Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years

被引：89

作者：

Cufer, Tanja ^{[1
]}

Ovcaricek, Tanja ^{[2
]}

O'Brien, Mary E. R. ^{[3
]}

机构：

[1] Univ Clin Golnik, Med Oncol Unit, Golnik 4204, Slovenia

[2] Univ Clin Ctr Maribor, Maribor 2000, Slovenia

[3] Royal Marsden Hosp, Sutton SM2 5RS, Surrey, England

来源：

EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷 / 06期

关键词：

Non-small cell lung cancer; Advanced disease; New systemic therapies; PHASE-III TRIAL; RECEPTOR TYROSINE KINASE; DOUBLE-BLIND; 1ST-LINE TREATMENT; MAINTENANCE THERAPY; OPEN-LABEL; DOUBLET CHEMOTHERAPY; WEEKLY PACLITAXEL; RANDOMIZED-TRIAL; ELDERLY-PATIENTS;

D O I：

10.1016/j.ejca.2012.11.021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The standard palliative treatment for advanced stage NSCLC remains a platinum doublet but by tailoring chemotherapy according to tumour histology the results can be improved through using pemetrexed-containing schemas in non-squamous-cell disease. In addition, maintenance chemotherapy appears to be effective in patients achieving clinical benefit by induction therapy. Targeted therapy based on the presence of activating epidermal growth factor receptor (EGFR) activating mutations or EML4-ALK gene rearrangement is becoming standard practice with high median survival rates, up to 30 months. There are still numerous other molecular targeted drugs in development. This review presents the most recent relevant progress in systemic anti-cancer therapy of advanced NSCLC in the past 5 years and delineates today's new treatment options. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：1216 / 1225

页数：10

共 70 条

[1] ALBERTI W, 1995, BRIT MED J, V311, P899
[2] [Anonymous], ENDOSC REV
[3] [Anonymous], ANN ONCOL S9
[4] Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis
Ardizzoni, Andrea
Boni, Luca
Tiseo, Marcello
Fossella, Frank V.
Schiller, Joan H.
Paesmans, Marianne
Radosavljevic, Davorin
Paccagnella, Adriano
Zatloukal, Petr
Mazzanti, Paola
Bisset, Donald
Rosell, Rafael
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (11) : 847 - 857
[5] Arnold AM, 2007, J CLIN ONCOL, V25, P4278, DOI 10.1200/JCO.2007.12.3083
[6] AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev plus Pemetrexed (pem) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)
Barlesi, F.
de Castro, J.
Dvornichenko, V.
Kim, J. H.
Pazzola, A.
Rittmeyer, A.
Vikstrom, A.
Mitchell, L.
Wong, E. K.
Gorbunova, V.
[J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : 16 - 16
[7] Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC)
Belani, C. P.
Waterhouse, D. M.
Ghazal, H.
Ramalingam, S. S.
Bordoni, R.
Greenberg, R.
Levine, R. M.
Waples, J. M.
Jiang, Y.
Reznikoff, G.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[8] Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study
Belani, Chandra P.
Brodowicz, Thomas
Ciuleanu, Tudor E.
Krzakowski, Maciej
Yang, Sung Hyun
Franke, Fabio
Cucevic, Branka
Madhavan, Jayaprakash
Santoro, Armando
Ramlau, Rodryg
Liepa, Astra M.
Visseren-Grul, Carla
Peterson, Patrick
John, William J.
Zielinski, Christoph C.
[J]. LANCET ONCOLOGY, 2012, 13 (03) : 292 - 299
[9] Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation
Belani, CP
Barstis, J
Perry, MC
La Rocca, RV
Nattam, SR
Rinaldi, D
Clark, R
Mills, GM
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2933 - 2939
[10] Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
Brodowicz, T
Krzakowski, M
Zwitter, M
Tzekova, V
Ramlau, R
Ghilezan, N
Ciuleanuf, T
Cucevic, B
Gyurkovits, K
Ulsperger, E
Jassem, J
Grgic, M
Pinar, S
Szilasi, M
Wiltschke, C
Wagnerova, M
Oskina, N
Soldatenkova, V
Zielinski, C
Wenczl, M
[J]. LUNG CANCER, 2006, 52 (02) : 155 - 163

← 1 2 3 4 5 6 7 →